Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 6729 - 6736 of 12140 results
Department of Veterans Affairs Aims to Trump State Telemedicine Rules
October 10, 2017| Blog| Viewpoint
Health Care Weekly Preview from ML Strategies – Week of October 9, 2017
October 10, 2017| Blog| Viewpoint
U.S. Visa Processing in Turkey Suspended Amid Security Concerns; Turkey Responds in Kind
October 10, 2017| Alert| Viewpoint
OTC Drug Manufacturers: Keep Your Eyes and Ears on Congress
October 10, 2017| Blog| Viewpoint
General Plastic Industrial Co. v. Canon Kabushiki Kaisha: PTAB Explains Factors for Follow-On Petitions
October 9, 2017| Blog| Viewpoint
Federal Trade Commission Announces Workshop on Competition in the Prescription Drug Market
October 9, 2017| Blog| Viewpoint
InsureTech Connect 2017 Panel Discussion: Maximizing Profits via Products and Alternative Business Model Innovation
October 9, 2017| Article| Viewpoint
3 Billion Compromised Yahoo Accounts May Yield Largest Plaintiff Class Ever
October 6, 2017| Blog| Viewpoint
News & Press Releases
Mintz Advises Charlesbank Capital Partners on Acquisition of Q6 Cyber
September 15, 2025
Mintz Advises on LB Pharmaceuticals’ $285 Million Initial Public Offering
September 12, 2025
Mintz advised the underwriters in connection with a $285 million initial public offering by LB Pharmaceuticals Inc of 19,000,000 shares of common stock at an initial public offering price of $15.00 per share. The aggregate gross proceeds to LB Pharmaceuticals from this offering were approximately $285 million before deducting underwriting discounts and commissions and other offering expenses. In addition, LB Pharmaceuticals granted the underwriters a 30-day option to purchase up to an additional 2,850,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The shares began trading on the Nasdaq Global Market on September 11, 2025 under the ticker symbol “LBRX.”
Mintz Advises the Placement Agents in CAMP4’s up to $100 Million Private Placement
September 12, 2025
Mintz advised the placement agents in connection with CAMP4's up to $100 million private placement. The private placement included upfront gross proceeds of $50 million in exchange for common stock (and pre-funded warrants in lieu of common stock for certain investors). In addition, CAMP4 will be eligible to receive up to an additional $50 million in gross proceeds in exchange for common stock (and pre-funded warrants for certain investors), subject to achieving pre-specified milestones, including receipt of regulatory clearance to initiate a Phase 1/2 clinical trial in SYNGAP patients with its development candidate, CMP-SYNGAP-01.
Events
Podcasts
Mintz On Air: Practical Policies – Disparage Me Not
August 26, 2025| Podcast|
Mintz On Air: Practical Policies - Investigations Unscripted
August 12, 2025| Podcast|
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|